These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
434 related articles for article (PubMed ID: 9041193)
1. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma. Takita J; Hayashi Y; Kohno T; Yamaguchi N; Hanada R; Yamamoto K; Yokota J Cancer Res; 1997 Mar; 57(5):907-12. PubMed ID: 9041193 [TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors. Heidenreich A; Gaddipati JP; Moul JW; Srivastava S J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401 [TBL] [Abstract][Full Text] [Related]
3. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Simoneau AR; Spruck CH; Gonzalez-Zulueta M; Gonzalgo ML; Chan MF; Tsai YC; Dean M; Steven K; Horn T; Jones PA Cancer Res; 1996 Nov; 56(21):5039-43. PubMed ID: 8895761 [TBL] [Abstract][Full Text] [Related]
5. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Martinsson T; Sjöberg RM; Hedborg F; Kogner P Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654 [TBL] [Abstract][Full Text] [Related]
6. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516 [TBL] [Abstract][Full Text] [Related]
7. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Pollock PM; Welch J; Hayward NK Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846 [TBL] [Abstract][Full Text] [Related]
8. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033 [TBL] [Abstract][Full Text] [Related]
9. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Thompson PM; Maris JM; Hogarty MD; Seeger RC; Reynolds CP; Brodeur GM; White PS Cancer Res; 2001 Jan; 61(2):679-86. PubMed ID: 11212268 [TBL] [Abstract][Full Text] [Related]
10. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Biden K; Young J; Buttenshaw R; Searle J; Cooksley G; Xu DB; Leggett B Hepatology; 1997 Mar; 25(3):593-7. PubMed ID: 9049204 [TBL] [Abstract][Full Text] [Related]
11. p16INK4 gene mutation and allelic loss of chromosome 9p21-22 in Taiwanese hepatocellular carcinoma. Chen TC; Hsieh LL; Kuo TT; Ng KF; Wu Chou YH; Jeng LB; Chen MF Anticancer Res; 2000; 20(3A):1621-6. PubMed ID: 10928081 [TBL] [Abstract][Full Text] [Related]
12. Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. Kim SK; Ro JY; Kemp BL; Lee JS; Kwon TJ; Fong KM; Sekido Y; Minna JD; Hong WK; Mao L Cancer Res; 1997 Feb; 57(3):400-3. PubMed ID: 9012464 [TBL] [Abstract][Full Text] [Related]
13. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Herman JG; Merlo A; Mao L; Lapidus RG; Issa JP; Davidson NE; Sidransky D; Baylin SB Cancer Res; 1995 Oct; 55(20):4525-30. PubMed ID: 7553621 [TBL] [Abstract][Full Text] [Related]
14. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910 [TBL] [Abstract][Full Text] [Related]
15. [Loss of heterozygosity on chromosome 9p13-23 in microdissected laryngeal squamous cell carcinoma by microsatellite analysis]. Xu X; An Q; Zhang J; Tang P; Cheng S Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Oct; 36(5):367-71. PubMed ID: 12761947 [TBL] [Abstract][Full Text] [Related]
16. CDKN2A/p16 is inactivated in most melanoma cell lines. Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma. Bazan V; Zanna I; Migliavacca M; Sanz-Casla MT; Maestro ML; Corsale S; Macaluso M; Dardanoni G; Restivo S; Quintela PL; Bernaldez R; Salerno S; Morello V; Tomasino RM; Gebbia N; Russo A J Cell Physiol; 2002 Sep; 192(3):286-93. PubMed ID: 12124774 [TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma. Obermann EC; Diss TC; Hamoudi RA; Munson P; Wilkins BS; Camozzi ML; Isaacson PG; Du MQ; Dogan A J Pathol; 2004 Feb; 202(2):252-62. PubMed ID: 14743509 [TBL] [Abstract][Full Text] [Related]
19. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. Kong XT; Choi SH; Inoue A; Xu F; Chen T; Takita J; Yokota J; Bessho F; Yanagisawa M; Hanada R; Yamamoto K; Hayashi Y Cancer Res; 1997 Sep; 57(17):3772-8. PubMed ID: 9288786 [TBL] [Abstract][Full Text] [Related]
20. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas. Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]